SB 728 T

Drug Profile

SB 728 T

Alternative Names: SB 728mR T; SB-728-T; ZFP Therapeutic

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antivirals; Cell therapies; Gene therapies; T lymphocyte cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action CCR5 receptor modulators; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 24 Feb 2016 Updated efficacy data from cohort 3 of a phase I/II trial in HIV infections released by Sangamo
  • 31 Mar 2015 SB 728 T is still in phase II trials for HIV infections in USA and Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top